Literature DB >> 20501769

Epidemiology of extracutaneous melanoma in the Netherlands.

Els R Koomen1, Esther de Vries, Leon C van Kempen, Alexander C J van Akkooi, Henk Jan Guchelaar, Marieke W J Louwman, Tamar Nijsten, Jan-Willem W Coebergh.   

Abstract

BACKGROUND: Reliable population-based incidence and survival data on extracutaneous melanoma (ECM) are sparse.
METHODS: Incidence data (1989-2006) from the Netherlands Cancer Registry were combined with vital status on January 1, 2008. Age-adjusted annual incidence rates were calculated by direct standardization, and the estimated annual percentage change was estimated to detect changing trends in incidence. Additionally, we carried out cohort-based relative survival analysis.
RESULTS: Ocular melanomas were the most common ECM subsite with European standardized incidence rates (ESR) of 10.7 and 8.2 per 1,000,000 person-years for males and females, respectively. In comparison, for cutaneous melanoma (CM), the ESRs for men and women were 122 and 155 per million person-years, respectively. No statistically significant trends in the incidence of ECM were detected, whereas an annual increase of 4.4% for men and 3.6% for women was detected in the incidence of CM. Relative survival for ECM was poor, but differed largely between anatomic subtypes ranging from a 5-year relative survival of 74% for ocular melanomas to 15% for certain subsites of mucosal melanomas.
CONCLUSIONS: Of all ECM subsites, ocular melanomas had the highest incidence and the best survival. Mucosal melanomas were the second most frequent subsite of ECM. Five-year relative survival for all ECM subtypes was worse if compared with CM. No statistically significant trends in the incidence of (subsites of) ECM were determined. IMPACT: This study gives insight into the relative sizes of the different subgroups of ECM as well as an estimate of 5-year survival, which varies substantially by subsite. Copyright 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20501769     DOI: 10.1158/1055-9965.EPI-09-1267

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

Review 1.  Primary Melanoma: from History to Actual Debates.

Authors:  Alessandro A E Testori; Stephanie A Blankenstein; Alexander C J van Akkooi
Journal:  Curr Oncol Rep       Date:  2019-12-19       Impact factor: 5.075

2.  Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.

Authors:  Olga Warszawik-Hendzel; Monika Słowińska; Małgorzata Olszewska; Lidia Rudnicka
Journal:  J Dermatol Case Rep       Date:  2014-09-30

3.  Inflammation and macrophage polarization in cutaneous melanoma: Histopathological and immunohistochemical study.

Authors:  Elisabetta Scali; Chiara Mignogna; Anna Di Vito; Ivan Presta; Caterina Camastra; Giuseppe Donato; Ugo Bottoni
Journal:  Int J Immunopathol Pharmacol       Date:  2016-07-07       Impact factor: 3.219

4.  Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.

Authors:  Sebastiaan P Prens; Augustinus P T van der Ploeg; Alexander C J van Akkooi; Cornelis A G M van Montfort; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2011-05-25       Impact factor: 5.344

5.  Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.

Authors:  Tim Schaefer; Imke Satzger; Ralf Gutzmer
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Mucosal melanomas in the racially diverse population of California.

Authors:  Lisa Altieri; Michael K Wong; David H Peng; Myles Cockburn
Journal:  J Am Acad Dermatol       Date:  2016-10-11       Impact factor: 15.487

7.  Predictors of mucosal melanoma survival in a population-based setting.

Authors:  Lisa Altieri; Megan Eguchi; David H Peng; Myles Cockburn
Journal:  J Am Acad Dermatol       Date:  2018-10-05       Impact factor: 15.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.